The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Special Article
PreviousPrevious
Volume 341:2061-2067 December 30, 1999 Number 27
NextNext

Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Laura F. Hutchins, M.D., Joseph M. Unger, M.S., John J. Crowley, Ph.D., Charles A. Coltman, M.D., and Kathy S. Albain, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Studies have documented the underrepresentation of women and blacks in clinical trials, and their recruitment is now federally mandated. However, little is known about the level of participation of elderly patients. We determined the rates of enrollment of patients 65 years of age or older in trials of treatment for cancer.

Methods We analyzed data on 16,396 patients consecutively enrolled in 164 Southwest Oncology Group treatment trials between 1993 and 1996 according to sex, race (black or white), and age under 65 years or 65 or older. These rates were compared with the corresponding rates in the general population of patients with cancer, derived from the 1990 U.S. Census and from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program for the period from 1992 through 1994. Fifteen types of cancer were included in the analysis.

Results The overall proportions of women and blacks enrolled in Southwest Oncology Group trials were similar to or the same as the estimated proportions in the U.S. population of patients with cancer (women, 41 percent and 43 percent; blacks, 10 percent and 10 percent, respectively). In contrast, patients 65 years of age or older were underrepresented overall (25 percent vs. 63 percent, P<0.001) and in trials involving all 15 types of cancer except lymphoma. The underrepresentation was particularly notable in trials of treatment for breast cancer (9 percent vs. 49 percent, P<0.001). The findings were similar when data on patients who were 70 years of age or older were analyzed, when 15 trials that excluded older patients were eliminated from the analysis, and when community-based enrollment was analyzed separately from enrollment at academic centers.

Conclusions There is substantial underrepresentation of patients 65 years of age or older in studies of treatment for cancer. The reasons should be clarified, and policies adopted to correct this underrepresentation.


Source Information

From the Department of Medicine, Division of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock (L.F.H.); the Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle (J.M.U., J.J.C.); the Department of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio (C.A.C.); and the Department of Medicine, Division of Hematology and Oncology, Loyola University Medical Center, Maywood, Ill. (K.S.A.).

Address reprint requests to the Southwest Oncology Group, Operations Office, 4980 Omicron Dr., San Antonio, TX 78245-3217, or to bgranados{at}swog.org.

Full Text of this Article


Related Letters:

Patients 65 Years of Age or Older in Cancer-Treatment Trials
Bartlett E. E., Copur M. S., Ledakis P., Muhvic J.
Extract | Full Text  
N Engl J Med 2000; 342:1531, May 18, 2000. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.